{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:46:37Z","timestamp":1785786397083,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jid.2022.03.039","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T20:27:48Z","timestamp":1671136068000},"page":"842-853.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9490","authenticated-orcid":false,"given":"Yuanyuan","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3353-6376","authenticated-orcid":false,"given":"Zhenyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1766-5311","authenticated-orcid":false,"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2204-2071","authenticated-orcid":false,"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.03.039_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2017.09.008","article-title":"MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor","volume":"409","author":"Aida","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jid.2022.03.039_bib2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1038\/s41467-018-05063-1","article-title":"Patterns of genomic evolution in advanced melanoma","volume":"9","author":"Birkeland","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2022.03.039_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2022.03.039_bib4","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1704371114","article-title":"Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma","volume":"114","author":"Duggan","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2022.03.039_bib5","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708446","article-title":"Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma","volume":"10","author":"Echevarr\u00eda-Vargas","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2022.03.039_bib6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jid.2017.09.056","article-title":"High MITF expression is associated with super-enhancers and suppressed by CDK7 inhibition in melanoma","volume":"138","author":"Eliades","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.039_bib7","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2022.03.039_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jid.2022.03.039_bib9","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103209","article-title":"Genome-wide cooperation of EMT transcription factor ZEB1 with YAP and AP-1 in breast cancer","volume":"39","author":"Feldker","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.jid.2022.03.039_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.celrep.2017.03.078","article-title":"Systematic epigenomic analysis reveals chromatin states associated with melanoma progression","volume":"19","author":"Fiziev","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2022.03.039_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2017.11.004","article-title":"Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene","volume":"68","author":"Fontanals-Cirera","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.jid.2022.03.039_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13072-019-0297-2","article-title":"MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells","volume":"12","author":"Fufa","year":"2019","journal-title":"Epigenet Chromatin"},{"key":"10.1016\/j.jid.2022.03.039_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2022.03.039_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/path.4318","article-title":"Molecular and genetic diversity in the metastatic process of melanoma","volume":"233","author":"Harbst","year":"2014","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jid.2022.03.039_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","article-title":"MITF in melanoma: mechanisms behind its expression and activity","volume":"72","author":"Hartman","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jid.2022.03.039_bib16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jid.2022.03.039_bib17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/jid.2015.105","article-title":"MITF modulates therapeutic resistance through EGFR signaling","volume":"135","author":"Ji","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.039_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","article-title":"A\u00a0melanocyte lineage program confers resistance to MAP kinase pathway inhibition","volume":"504","author":"Johannessen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.03.039_bib19","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2022.03.039_bib20","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.celrep.2016.07.079","article-title":"Differential chromosomal localization of centromeric histone CENP-A contributes to nematode programmed DNA elimination","volume":"16","author":"Kang","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jid.2022.03.039_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-021-01974-y","article-title":"Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance","volume":"40","author":"Li","year":"2021","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jid.2022.03.039_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jid.2022.03.039_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2159-8290.CD-14-0295","article-title":"EphA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma","volume":"5","author":"Miao","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2022.03.039_bib24","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2022.03.039_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/cancers12020482","article-title":"Current advances in the treatment of BRAF-mutant melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2022.03.039_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.03.039_bib27","doi-asserted-by":"crossref","first-page":"8755","DOI":"10.1038\/ncomms9755","article-title":"MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment","volume":"6","author":"Riesenberg","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2022.03.039_bib28","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2022.03.039_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.jid.2022.03.039_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/2159-8290.CD-13-0279","article-title":"A\u00a0novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2022.03.039_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.03.039_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020. CA","volume":"70","author":"Siegel","year":"2020","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.jid.2022.03.039_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OTT.S39096","article-title":"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies","volume":"8","author":"Spagnolo","year":"2015","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.jid.2022.03.039_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jid.2022.03.039_bib33","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/cancers12082154","article-title":"EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment","volume":"12","author":"Tang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2022.03.039_bib34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jid.2014.418","article-title":"Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas","volume":"135","author":"Wang","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.03.039_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jid.2022.03.039_bib36","doi-asserted-by":"crossref","first-page":"28087","DOI":"10.1074\/jbc.M112.377218","article-title":"Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)\/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma","volume":"287","author":"Yadav","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2022.03.039_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jss.2014.02.021","article-title":"Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor","volume":"190","author":"Zeiderman","year":"2014","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jid.2022.03.039_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-017-0320-y","article-title":"Combinatorial therapies in melanoma: MAPK inhibitors and beyond","volume":"19","author":"Zhou","year":"2018","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22028305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X22028305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:33:21Z","timestamp":1758303201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X22028305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0022202X22028305"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.03.039","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}